[HTML][HTML] Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings
PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer
(PCa), but its clinical use was promptly extended to detection, staging and therapy response …
(PCa), but its clinical use was promptly extended to detection, staging and therapy response …
Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology
JF Gomes Marin, RF Nunes, AM Coutinho… - Radiographics, 2020 - pubs.rsna.org
Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients …
Purpose: Prostate specific membrane antigen-targeted positron emission tomography/
computerized tomography has the potential to improve the detection and localization of …
computerized tomography has the potential to improve the detection and localization of …
[HTML][HTML] Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …
prostate cancer have improved outcomes, but there are still many aspects of management …
[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm …
Summary Background National Comprehensive Cancer Network guidelines consider 18 F-
fluciclovine PET-CT for prostate cancer biochemical recurrence localisation after radical …
fluciclovine PET-CT for prostate cancer biochemical recurrence localisation after radical …
Detection efficacy of 18F-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy
FL Giesel, K Knorr, F Spohn, L Will… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA)–targeted PET imaging recently emerged as a
new method for the staging and restaging of prostate cancer. Most published studies …
new method for the staging and restaging of prostate cancer. Most published studies …
Matched-pair comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical …
I Rauscher, M Krönke, M König, A Gafita… - Journal of nuclear …, 2020 - Soc Nuclear Med
18F-labeled prostate-specific membrane antigen (PSMA)–ligand PET has several principal
advantages over 68Ga-PSMA-11. The purpose of this retrospective study was to evaluate …
advantages over 68Ga-PSMA-11. The purpose of this retrospective study was to evaluate …
Optimum imaging strategies for advanced prostate cancer: ASCO guideline
PURPOSE Provide evidence-and expert-based recommendations for optimal use of
imaging in advanced prostate cancer. Due to increases in research and utilization of novel …
imaging in advanced prostate cancer. Due to increases in research and utilization of novel …
[68Ga] Ga-PSMA versus [18F] PSMA positron emission tomography/computed tomography in the staging of primary and recurrent prostate cancer. A systematic review …
L Evangelista, T Maurer, H van der Poel… - European Urology …, 2022 - Elsevier
Context In the past 10 yr, several agents based on prostate-specific membrane antigen
(PSMA) for positron emission tomography imaging have been introduced in clinical practice …
(PSMA) for positron emission tomography imaging have been introduced in clinical practice …